Haverford Trust Co Lowers Stock Position in Johnson & Johnson $JNJ

Key Points

• Haverford Trust Co reduced its holdings in Johnson & Johnson by 1.6%, owning 1,147,774 shares worth approximately $190.35 million at the end of the first quarter.
• Johnson & Johnson's stock has seen significant interest from institutional investors, with notable acquisitions revealing a strong market presence, as they currently hold 69.55% of the company's stock.
• The company recently announced a quarterly dividend of $1.30, representing a 2.9% dividend yield, with a payout ratio of 55.61%.

Haverford Trust Co decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,147,774 shares of the company's stock after selling 18,521 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Haverford Trust Co's portfolio, making the stock its 18th largest holding. Haverford Trust Co's holdings in Johnson & Johnson were worth $190,347,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $49,000. Capital A Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Trading Up 0.1%

Shares of NYSE:JNJ traded up $0.1680 during trading on Friday, reaching $179.0980. The stock had a trading volume of 9,523,149 shares, compared to its average volume of 8,657,504. The stock has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The firm's fifty day moving average is $163.48 and its 200 day moving average is $159.30. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the firm earned $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.